AzTrials
AzTrials

Friedreich AtaxiaPhase 3BRAVENCT06953583

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

A Phase 3 study testing Omaveloxolone in people with Friedreich Ataxia, run by Biogen at 34 sites in 16 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older. However, it is not yet available for younger teens and children. Read more about this study

Who is it for?
Ages 2 to 15 years
Conditions the study is for
Friedreich Ataxia
What is being tested?
Omaveloxolone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
255 participants
Where
34 sitesin 16 countries
Study dates
9 Jun 2025to 22 Nov 2029
Phase
Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 15 years
  • All sexes
  • No healthy volunteers
  • Child

Part 1: Key inclusion criteria:

  • Diagnosed with genetically confirmed Friedreich's Ataxia (FA), i.e., homozygous for guanine-adenine-adenine (GAA) repeat expansion in intron-1 of the frataxin gene, or GAA repeat expansion in 1 allele and with point mutations or deletions, or other non-GAA expansion mutations in the other allele.
  • Symptomatic for FA as confirmed by clinician assessment. a. Children 7 to < 16 years must also have an upright stability score (USS) score of 10 to ≤ 34 at baseline

Part 1: Key exclusion criteria:

  • Glycosylated hemoglobin A1C (HbA1c) > 11%
  • B-type natriuretic peptide (BNP) > 200 picograms per milliliter (pg/mL) at screening
  • Ejection fraction (EF) < 40% [based on echocardiogram (ECHO) performed at screening visit]
  • Clinically significant cardiac disease except mild to moderate cardiomyopathy

Part 2A: Eligibility criteria:

  • They have completed Part 1 of the study and no discontinuation criteria have been met.
  • Safety and tolerability data from Part 1 are supportive of continuation in the judgement of the investigator.

Part 2B: Eligibility criteria:

  • Participants have completed Part 1 of the study and no discontinuation criteria have been met.
  • Safety and tolerability data from Part 1 are supportive of continuation in the judgement of the Investigator.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

34 sites in 16 countries.

34 sites in 16 countries

United States7 sites
  • Norman Fixel Institute for Neurological Diseases UF Health

    Gainesville, Florida, 32610-3010

  • UCLA Neurology Outpatient Clinic at Westwood

    Los Angeles, California, 90095

  • St. Jude Children's Research Hospital - PIN

    Memphis, Tennessee, 38105-3678

  • CHKD's Health Center - South Campus - PIN

    Norfolk, Virginia, 23507-1910

  • Children's Hospital of Philadelphia - Buerger Center for Advanced Pediatric Care - PIN

    Philadelphia, Pennsylvania, 19104

  • Seattle Children's Hospital

    Seattle, Washington, 98105-3901

  • USF Health Morsani College of Medicine Department of Neurology

    Tampa, Florida, 33612

Other trials in United States

Brazil3 sites
  • L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME

    Brasília, Federal District, 70200-730

  • University of Campinas (UNICAMP) School of Medical Sciences

    Campinas, São Paulo, 13083-970

  • PSEG Centro de Pesquisa Clinica

    São Paulo, São Paulo, 04024-002

Other trials in Brazil

Germany3 sites
  • Universitätsklinikum Aachen

    Aachen, North Rhine-Westphalia, 52074

  • UKGM - Universitätsklinikum Giessen und Marburg GmbH - Standort Gießen

    Giessen, 35392

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, 20246

Other trials in Germany

Italy3 sites
  • IRCCS Eugenio Medea - Polo. Scientifico Veneto

    Conegliano, Veneto, 31015

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, 20133

  • Ospedale Pediatrico Bambino Gesù IRCCS

    Rome, Lazio, 165

Other trials in Italy

United Kingdom3 sites
  • University College Hospital - PPDS

    London, Lincolnshire, NW1 2BU

  • John Radcliffe Hospital

    Oxford, Oxfordshire, OX3 9DU

  • Sheffield Children's Hospital - PPDS

    Sheffield, South Yorkshire, S10 5DD

Other trials in United Kingdom

Australia2 sites
  • Murdoch Childrens Research Institute (MCRI)

    Parkville, Victoria, 3052

  • Sydney Children's Hospital

    Randwick, New South Wales, 2031

Other trials in Australia

Canada2 sites
  • McGill University

    Montreal, Quebec, H3H 2R9

  • CHU de Quebec -Universite Laval

    Québec, Quebec, G1V 4G2

Other trials in Canada

France2 sites
  • CHU de Montpellier- Hôpital Gui De Chauliac

    Montpellier, Hérault, 34090

  • AP-HP - Hôpital Armand Trousseau

    Paris, 75012

Other trials in France

Spain2 sites
  • Hospital Sant Joan de Deu - PIN

    Espluges de Llobregat, Barcelona, 8950

  • Hospital Universitario La Paz - PPDS

    Madrid, 28046

Other trials in Spain

Austria1 site
  • Universitätsklinikum Innsbruck

    Innsbruck, 6020

Other trials in Austria

Denmark1 site
  • Rigshospitalet - Juliane Marie Centret (JMC) Copenhagen

    Copenhagen, 2100

Other trials in Denmark

India1 site
  • All India Institute of Medical Sciences (AIIMS) - New Delhi

    New Delhi, National Capital Territory of Delhi, 110029

Other trials in India

Ireland1 site
  • CHI at Temple Street

    Dublin, D01 XD99

Other trials in Ireland

Netherlands1 site
  • Radboud Universitair Medisch Centrum

    Nijmegen, 6525 GA

Other trials in Netherlands

Saudi Arabia1 site
  • King Faisal Specialist Hospital & Research Centre

    Riyadh, Ar Riya, 12875

Other trials in Saudi Arabia

Turkey (Türkiye)1 site
  • Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi

    Istanbul, 34093

Other trials in Turkey (Türkiye)

About this study

Official title: A Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich's Ataxia Aged 2 to < 16 Years

In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older. However, it is not yet available for younger teens and children. The main goal of this study is to learn how omaveloxolone affects symptoms of FA and its safety in younger participants between the ages of 2 and 15 years old.

The main questions researchers want to answer in this study are:

Read more
  • How does omaveloxolone affect the participants' FA symptoms?
  • How does the body process omaveloxolone?
  • How many participants have adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
  • Are there any changes in the participants' overall health or heart health? Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to test nerve function. The mFARS tests movement ability, balance, coordination, speech, and arm and leg functions. More specifically, researchers will check participants' balance, coordination, movement, and ability to perform daily tasks using the Upright Stability Score (USS). The USS is part of the mFARS questionnaire.

Researchers will also use other questionnaires to learn more about participants' symptoms, quality of life, ability to perform daily living activities, and how severe participants think their disease is.

Researchers will also note any changes as participants go through puberty. Some participants may also be invited to take part in interviews about their experiences during the study or wear devices that measure movement and physical activity during daily life.

This study will be done in 2 parts as follows:

  • Participants will be screened for up to 4 weeks to check if they can join the study.
  • In Part 1, participants will be randomly assigned to take either omaveloxolone or a placebo by mouth once a day for about 1 year. A placebo looks like the study drug but contains no real medicine.
  • Part 1 will be double blind. This means that the participants, study doctors, and study staff will not know if the participants are receiving omaveloxolone or a placebo.
  • Including screening, participants will have up to 9 clinic visits and 1 phone call during Part 1. If a participant does not join Part 2, they will have another safety follow-up phone call a month after their last dose of omaveloxolone.
  • Participants who finish Part 1 may move onto Part 2. During Part 2, participants who are at least 7 years old will be randomly assigned to receive either 150 mg or 250 mg of omaveloxolone once a day for about 104 weeks. Participants younger than 7 years old will receive 150 mg of omaveloxolone once a day for about 104 weeks.
  • During Part 2, participants will have up to 8 clinic visits and 1 phone call. Participants will also have a follow-up phone call about a month after they stop taking omaveloxolone.
  • In total, participants will have up to 17 clinic visits and 3 phone calls. Each participant will be in the study for up to 3 years.
Read the detailed description

The primary objective of Part 1 is to evaluate the efficacy of omaveloxolone as measured by upright stability score (USS) and the secondary objectives are to evaluate the efficacy of omaveloxolone as measured by additional secondary efficacy outcomes, safety of omaveloxolone and the plasma concentration of omaveloxolone after single and multiple dose administration.

The primary objective of Part 2A is to evaluate the efficacy of omaveloxolone and the secondary objectives are to characterize the efficacy of omaveloxolone as measured by additional secondary outcomes, evaluate the safety and tolerability of omaveloxolone and plasma concentration of omaveloxolone after single and multiple dose administration.

The primary objective for Part 2B is to evaluate the safety and tolerability of long-term omaveloxolone use and the secondary objective is to evaluate the efficacy of omaveloxolone following long-term use.

Being tested
Omaveloxolone, Placebo
Medical subject headings
Friedreich Ataxia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OmaveloxoloneDrug

    Also called BIIB141, SKYCLARYS, RTA-408

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Study groups in NCT06953583
Study groupRoleWhat they receive
Part 1: OmaveloxoloneExperimentalParticipants will receive a single oral dose of omaveloxolone once a day (QD) for up to 52 weeks in Part 1 of the study.
Receives: Drug: Omaveloxolone
Part 1: PlaceboPlacebo comparatorParticipants will receive placebo, orally, QD for up to 52 weeks in Part 1 of the study.
Receives: Drug: Placebo
Part 2A Continued Efficacy Evaluation: OmaveloxoloneExperimentalParticipants will receive a single oral dose of omaveloxolone, QD for up to 104 weeks in Part 2A of the study.
Receives: Drug: Omaveloxolone
Part 2B Safety: OmaveloxoloneExperimentalParticipants will receive a single oral dose of open-label omaveloxolone, QD for up to 104 weeks in Part 2B of the study.
Receives: Drug: Omaveloxolone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part 1: Change From Baseline in Upright Stability Score (USS) Subscale E of Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 52

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Measured: Baseline, Week 52

  2. Part 2A: Change From Baseline in USS Subscale E of mFARS at Week 52

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Measured: Baseline (Week 52 of Part 1), Week 52

  3. Part 2B: Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (TESAE)

    Measured: From the first dose of the study drug in Part 2B up to the end of follow-up period in Part 2B (up to Week 104)

  4. Part 2B: Number of Participants With Change From Baseline in Cardiac Function Assessed by Echocardiogram (ECHO) at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  5. Part 2B: Change From Baseline in Height at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  6. Part 2B: Change From Baseline in Weight at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  7. Part 2B: Change From Baseline in Body Mass Index (BMI) at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  8. Part 2B: Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Weeks 52 and Week 104

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment of individuals ≥ 6 years of age. The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered by the clinician during any evaluation or risk assessment to identify the level and type of suicidality present. The assessment includes "yes" or "no" responses for 5 questions each, related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation, from 1 to 5, with 5 being the most severe.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  9. Part 2B: Percentage of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  10. Part 2B: Number of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

Secondary outcomes (30)
  1. Part 1: Change From Baseline in Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 52

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Measured: Baseline, Week 52

  2. Part 1: Change From Baseline in Friedreich's Ataxia-Health Index (FA-HI) at Week 52

    The FA-HI is a participant reported survey that assesses overall disease burden on a 100-point scale, with 0 representing no disease burden and 100 representing the maximum level of disease burden containing 113 symptoms questions representing 18 symptomatic subscales.

    Measured: Baseline, Week 52

  3. Part 1: Change From Baseline in Friedreich's Ataxia-Activities of Daily Living (FA-ADL)

    Participants will answer the 9 questions of the FA-ADL survey in an interview style conducted by any site staff. The FA-ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function.

    Measured: Baseline, Week 52

  4. Part 1: Change From Baseline in Clinical Global Impressions-Severity (CGI-S) at Week 52

    The CGI-S will be conducted for all enrolled participants, 2 to < 16 years of age. The CGI-S rating evaluates the severity of individual symptoms and treatment response in participants with mental disorders. The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.

    Measured: Baseline, Week 52

  5. Part 1: Change From Baseline in Patient Global Impressions-Severity (PGI-S) at Week 52

    PGI-S will be conducted for participants 7 to < 16 years of age. These are clinically meaningful outcome measures that are participant-relevant across all age groups and disease severities for this population. PGI -S is a 1-item questionnaire where the response is recorded on a 4-point scale scored as: 1-normal, 2-mild, 3-moderate, or 4-severe.

    Measured: Baseline, Week 52

  6. Part 1: Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (TESAE)

    Measured: From first dose of study drug up to end of follow up period in Part 1 (up to Week 52)

  7. Part 1: Number of Participants With Change From Baseline in Cardiac Function Assessed by ECHO at Week 52

    Measured: Baseline, Week 52

  8. Part 1: Change From Baseline in Height at Week 52

    Measured: Baseline, Week 52

  9. Part 1: Change From Baseline in Weight at Week 52

    Measured: Baseline, Week 52

  10. Part 1: Change From Baseline in Body Mass Index (BMI) at Week 52

    Measured: Baseline, Week 52

  11. Part 1: Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Week 52

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment of individuals ≥ 6 years of age. The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered by the clinician during any evaluation or risk assessment to identify the level and type of suicidality present. The assessment includes "yes" or "no" responses for 5 questions each, related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation, from 1 to 5, with 5 being the most severe.

    Measured: Baseline, Week 52

  12. Part 1: Percentage of Participants at Each Tanner Stage at Week 52

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Measured: Baseline, Week 52

  13. Part 1: Number of Participants at Each Tanner Stage at Week 52

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Measured: Baseline, Week 52

  14. Part 1: Plasma Concentrations of Omaveloxolone

    Measured: Pre-dose and post-dose on Day 1, Weeks 4, 12 and 26

  15. Part 2A: Change From Baseline in USS Subscale E of mFARS at Week 104

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Measured: Baseline (Week 52 of Part 1), Week 104

  16. Part 2A: Change from baseline in mFARS at Weeks 52 and Week 104

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  17. Part 2A: Number of Participants With TEAE and TESAE

    Measured: From the first dose of the study drug in Part 2A up to the end of follow-up period in Part 2A (up to Week 104)

  18. Part 2A: Number of Participants With Change From Baseline in Cardiac Function Assessed by ECHO at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  19. Part 2A: Change From Baseline in Height at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  20. Part 2A: Change From Baseline in Weight at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  21. Part 2A: Change From Baseline in BMI at Weeks 52 and Week 104

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  22. Part 2A: Change From Baseline in C-SSRS at Weeks 52 and Week 104

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment of individuals ≥ 6 years of age. The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered by the clinician during any evaluation or risk assessment to identify the level and type of suicidality present. The assessment includes "yes" or "no" responses for 5 questions each, related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation, from 1 to 5, with 5 being the most severe.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  23. Part 2A: Percentage of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  24. Part 2A: Number of Participants at Each Tanner Stage at Weeks 52 and Week 104

    Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  25. Part 2A: Plasma Concentrations of Omaveloxolone

    Measured: Pre-dose and post-dose on Day 1, Weeks 4, 12 and 26

  26. Part 2B: Change From Baseline in mFARS Including USS at Weeks 52 and Week 104

    The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  27. Parts 2A and 2B: Change From Baseline in FA-HI at Weeks 52 and Week 104

    The FA-HI is a participant reported survey that assesses overall disease burden on a 100-point scale, with 0 representing no disease burden and 100 representing the maximum level of disease burden containing 113 symptoms questions representing 18 symptomatic subscales.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  28. Parts 2A and 2B: Change From Baseline in PGI-S at Weeks 52 and Week 104

    PGI-S will be conducted for participants 7 to < 16 years of age. These are clinically meaningful outcome measures that are participant-relevant across all age groups and disease severities for this population. PGI -S is a 1-item questionnaire where the response is recorded on a 4-point scale scored as: 1-normal, 2-mild, 3-moderate, or 4-severe.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  29. Parts 2A and 2B: Change From Baseline in CGI-S at Weeks 52 and Week 104

    The CGI-S will be conducted for all enrolled participants, 2 to < 16 years of age. The CGI-S rating evaluates the severity of individual symptoms and treatment response in participants with mental disorders. The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

  30. Parts 2A and 2B: Change from baseline in FA-ADL at Part 2A Weeks 52 and Week 104

    Participants will answer the 9 questions of the FA-ADL survey in an interview style conducted by any site staff. The FA-ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function.

    Measured: Baseline (Week 52 of Part 1), Weeks 52 and 104

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2025
  2. Study start9 Jun 2025
  3. Primary completion16 Nov 2027 (estimated)
  4. Study completion22 Nov 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
255 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06953583
Sponsor's protocol ID
296FA301
Other IDs
2025-520896-13, 2025
Acronym
BRAVE
Status last verified
Sep 2026
First submitted
11 Apr 2025
Last updated
2 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in